A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

M
Mark Tann, MD

Primary Investigator

Overview

The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.

Description

The purpose of this study is to look at the safety of radioembolization therapy with Yttrium 90 for liver disease.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    liver disease,HCC,liver cancer,hepatocellular carcinoma
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Subjects must have a diagnosis of hepatocellular carcinoma (HCC) and a treatment plan to undergo radioembolization therapy with Y-90 at Indiana University Health Hospital.
  • Subjects must be willing and able to comply with all procedures and visits required for this protocol (pre-treatment, during treatment, and post-treatment).

For a full list of participation criteria, please visit clinicaltrials.gov.


Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1606072855 (RADY-BTG-TANN-HIDA/0603)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center